Retrophin Inc said on Thursday it was discontinuing the late-stage study for its rare neurological disorder treatment after it failed to improve patients' ability to conduct daily activities such as eating and walking, sending shares down 30%.
Medtronic Plc beat analysts' estimates for quarterly profit on Tuesday, boosted by higher demand for its surgical instruments and diabetes devices, and the medical device maker raised its forecast for full-year adjusted profit as well.
The U.S. Food and Drug Administration on Friday approved Celgene Corp's Inrebic to treat certain rare forms of bone marrow cancer called myelofibrosis, making it the second approved drug to treat the disease.
Deciphera Pharmaceuticals Inc's shares more than doubled on Tuesday after the drugmaker said its treatment helped stomach cancer patients live longer without their disease worsening in a late-stage study.
Health insurer Humana Inc raised its 2019 profit forecast on Wednesday and beat second-quarter earnings estimates, as it reined in costs and recorded higher revenue from its unit that sells Medicare Advantage health plans.
The U.S. Food and Drug Administration has approved Merck & Co Inc's combination treatment for complicated forms of urinary tract and abdominal infections, the drugmaker said on Wednesday.
July 17 The U.S. Food and Drug Administration
has approved Merck & Co Inc's combination treatment for
complicated forms of urinary tract and abdominal infections, the
drugmaker said on Wednesday.
Walgreens Boots Alliance Inc on Thursday posted a better-than-expected quarterly profit as the drugstore chain benefited from a rise in branded drug prices and an increase in the number of prescriptions it fills in the United States.